GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$50.67
-1.48 (-2.84%)
▼
5d:
-4.14%
30d:
-0.74%
90d:
-3.25%
BUY
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GSK shows positive signals but monitor for confirmation. Market pricing in 2.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GSK shows positive signals but monitor for confirmation. Market pricing in 2.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$73.64
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$45.73
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $50.67, which is considered fair relative to its 30-day fair value range of $50.08 to $52.01. The stock's valuation (Forward PE: 9.7) is in line with its historical norms (10.5). Remarkably, the market is currently pricing in an annual earnings decline of 2.8% over the next few years. This pessimistic expectation contrasts with the company's recent 8.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GSK is in a strong downtrend. The price is currently testing key support at $50.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $56.63 (+11.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a strong downtrend. The price is currently testing key support at $50.35. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $56.63 (+11.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$50.08 -
$52.01
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($56.63)
Trading Range Analysis
30-Day Trading Range
$50.08 -
$52.01
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$50.35
Resistance Level
$53.45
Current Trend
Strong Downtrend
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.69
Wall Street Target
$56.63
(+11.8%)
Revenue Growth (YoY)
1.5%
Earnings Growth (YoY)
8.4%
Profit Margin
17.8%
Valuation Discount vs History
-2.8% cheaper
PE vs Historical
9.7 vs 10.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.8%
(market-implied from PE analysis)
1-Year Target
$49.25
(-3%)
2-Year Target
$47.87
(-6%)
3-Year Target
$46.53
(-8%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$50.44
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 8.1%)
$143.73
(+184%)
Base:
(SPY PE: 9.7, Growth: 8.1%)
$63.92
(+26%)
Bear:
(PE: 8.2, Growth: 8.1%)
$54.33
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 13.65 | Current EPS (TTM): $3.82
Bull Case
$78.56
(+55%)
Analyst growth 36.9%, PE expands to 15.0
Base Case
$71.41
(+41%)
Market implied 36.9%, PE stable at 13.7
Bear Case
$35.46
(-30%)
Severe decline -20.0%, PE contracts to 11.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.7 to 10.5
Stabilization Target:
$54.93
(+8.4%)
PE Expansion Potential:
+8.4%
Share & Embed Analysis
Last updated: June 21, 2026 12:48 AM ET
Data refreshes hourly during market hours. Next update: 1:48 AM
Data refreshes hourly during market hours. Next update: 1:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1216 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 58 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 57 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$221 | 58 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 53 HOLD |
